cilostazol / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 86 Diseases   33 Trials   33 Trials   1472 News 


«12...6789101112131415161718»
  • ||||||||||  aripiprazole / Generic mfg., Pletal (cilostazol) / Otsuka
    Preclinical, Journal:  Multitarget-directed cotreatment with cilostazol and aripiprazole for augmented neuroprotection against oxidative stress-induced toxicity in HT22 mouse hippocampal cells. (Pubmed Central) -  Jan 16, 2020   
    Consequently, this cotreatment synergistically ameliorated the attenuated neurite outgrowth induced by HO in the HT22 cells, and these were inhibited by K252A (inhibitor of BDNF receptor), TBCA (CK2 inhibitor), imatinib (β-catenin inhibitor) and ZnPP (inhibitor of HO-1), indicating that BDNF, P-CK2α, β-catenin and HO-1 activation are implicated in the enhanced neurite outgrowth. This study highlights that cotreatment with low concentrations of aripiprazole and cilostazol synergistically elicits neuroprotective effects by overcoming oxidative stress-evoked neurotoxicity associated with increased neurite outgrowth, providing a rationale for the use of this combinatorial treatment in vascular dementia.
  • ||||||||||  Pletal (cilostazol) / Otsuka
    Journal:  The use of cilostazol for secondary stroke prevention: isn't time to be evaluated in Western countries? (Pubmed Central) -  Jan 16, 2020   
    This study highlights that cotreatment with low concentrations of aripiprazole and cilostazol synergistically elicits neuroprotective effects by overcoming oxidative stress-evoked neurotoxicity associated with increased neurite outgrowth, providing a rationale for the use of this combinatorial treatment in vascular dementia. No abstract available
  • ||||||||||  Pletal (cilostazol) / Otsuka
    Clinical, Journal:  Large vessel vasculopathy in a patient with systemic lupus erythematosus: a case report. (Pubmed Central) -  Jan 5, 2020   
    Trial registration: http://clinicaltrials.gov : NCT01409564. Large vessel vasculopathy should be considered another potential cause of arterial stenoses and occlusion in patients with lupus when they have peripheral arterial disease despite having no atherosclerotic risk factors.
  • ||||||||||  fluorouracil / Generic mfg.
    Clinical, Journal:  A Case Report of Luminal A Male Inflammatory Breast Cancer that Was Difficult to Treat Because of Trousseau Syndrome (Pubmed Central) -  Dec 26, 2019   
    The condition of the disease was stabilized by FEC (5-FU, epirubicin, cyclophosphamide) therapy, but it became difficult to secure the blood vessel...This case of inflammatory luminal in male breast cancer that caused thrombus was difficult to treat. Thrombosis in advanced cancer patients is often pointed out, but since male breast cancer patients tend to take a long time to visit the hospital after becoming aware of the mass and arrive at an advanced state, it is necessary to notify the public of the existence of male breast cancer.
  • ||||||||||  Pletal (cilostazol) / Otsuka
    Journal:  Cilostazol inhibits hyperglucose-induced vascular smooth muscle cell dysfunction by modulating the RAGE/ERK/NF-κB signaling pathways. (Pubmed Central) -  Dec 26, 2019   
    Thrombosis in advanced cancer patients is often pointed out, but since male breast cancer patients tend to take a long time to visit the hospital after becoming aware of the mass and arrive at an advanced state, it is necessary to notify the public of the existence of male breast cancer. Both in vitro and in vivo experimental diabetes models showed novel signal transduction of cilostazol-mediated protection against HG-related VSMC dysfunction, and highlighted the involvement of RAGE signaling and downstream pathways.
  • ||||||||||  Pletal (cilostazol) / Otsuka
    Journal:  MicroRNA-132 targeting PTEN contributes to cilostazol-promoted vascular smooth muscle cell differentiation. (Pubmed Central) -  Dec 21, 2019   
    Both in vitro and in vivo experimental diabetes models showed novel signal transduction of cilostazol-mediated protection against HG-related VSMC dysfunction, and highlighted the involvement of RAGE signaling and downstream pathways. These results suggest that miR-132 by targeting PTEN may be an important regulator in mediating cilostazol actions on VSMC differentiation.
  • ||||||||||  Pletal (cilostazol) / Otsuka
    Tenascin-C: A Novel Therapeutic Target in Subarachnoid Hemorrhage (Hall H) -  Dec 21, 2019 - Abstract #ISC2020ISC_2213;    
    The 300 mg/day cilostazol may improve post-SAH outcomes by reducing plasma TNC levels and delayed cerebral infarction. Further investigations may provide a novel therapeutic approach targeting TNC.
  • ||||||||||  aspirin / Generic mfg., Pletal (cilostazol) / Otsuka
    Cilostazol versus Aspirin for Secondary Stroke Prevention: Systematic Review and Meta-Analysis (Hall H) -  Dec 21, 2019 - Abstract #ISC2020ISC_590;    
    This meta-analysis suggests cilostazol is more effective than aspirin in the prevention of recurrent ischemic stroke with lower risk of intracranial hemorrhage and bleeding. Confirmatory randomized trials of cilostazol for secondary stroke prevention to be performed in more generalizable populations are needed.
  • ||||||||||  Pletal (cilostazol) / Otsuka
    Cilostazol effective? (Con) (Room 515 B) -  Dec 21, 2019 - Abstract #ISC2020ISC_6;    
    Additional effects of cilostazol to prevent cardiovascular event or any death, and bleeding event were not confirmed. There is no abstract associated with this presentation.
  • ||||||||||  Pletal (cilostazol) / Otsuka
    CSPS.com for cilostazol (Pro) (Room 515 B) -  Dec 21, 2019 - Abstract #ISC2020ISC_5;    
    There is no abstract associated with this presentation. There is no abstract associated with this presentation.
  • ||||||||||  Pletal (cilostazol) / Otsuka
    Preclinical, Journal:  Anti-TNF effect of combined pravastatin and cilostazol treatment in an in vivo mouse model. (Pubmed Central) -  Dec 6, 2019   
    The combination therapy comprising cilostazol and statins, particularly pravastatin, exerted the best anti-TNF effect compared with clopidogrel and statin therapy; thus, a suitable combination therapy, such as CILOP, can be a potential remedy to cure TNF-related diseases. These findings suggest that combined pravastatin and cilostazol is more effective for reducing TNF-driven inflammation through their anti-TNF activity than monotherapy.
  • ||||||||||  Pletal (cilostazol) / Otsuka, warfarin / Generic Mfg.
    Clinical, Journal:  Critical limb ischemia in a patient with systemic lupus erythematosus: a case report. (Pubmed Central) -  Nov 27, 2019   
    Critical limb ischemia is a rare complication of systemic lupus erythematosus that requires immediate treatment. Due to our limited resources, we improvised a strategy to achieve the best possible outcome in our patient by using a combination of invasive treatment and medication.
  • ||||||||||  Pletal (cilostazol) / Otsuka
    Biomarker, Journal:  Citrullinated Histone H3: Early Biomarker of Neutrophil Extracellular Traps in Septic Liver Damage. (Pubmed Central) -  Nov 19, 2019   
    These results suggest that the safety and effectiveness of cilostazol treatment were sustained in patients with femoropopliteal disease undergoing endovascular treatment. H3Cit is a useful biomarker for early detection of NETosis or liver dysfunction, and Ciz may be an effective treatment for septic liver damage.
  • ||||||||||  pentoxifylline / Generic Mfg., Pletal (cilostazol) / Otsuka
    Clinical, Journal:  Clinical study of efficacy and safety of Aducil in patients with chronic lower limb ischaemia (Pubmed Central) -  Nov 10, 2019   
    Our results suggest that cilostazol may have potential as a promising therapeutic drug for treatment of ALD. Analysis of the study endpoints demonstrated that Aducil® had better treatment effectiveness in patients with chronic lower limb ischemia stage IIB according to the classification of A.V. Pokrovsky-Fontaine as compared with Trental® 400, while the safety profile and drug tolerance were similar between the two.
  • ||||||||||  Clinical, Journal:  An update on novel antiplatelets in vascular patients. (Pubmed Central) -  Nov 8, 2019   
    Other novel antiplatelets demonstrate positive results, but further studies focused on vascular patients are necessary. Novel experimental antiplatelets are still in early phases of the clinical and preclinical studies.
  • ||||||||||  Pletal (cilostazol) / Otsuka
    Clinical, Journal:  Significance of Coronary Artery Spasm Diagnosis in Patients With Early Repolarization Syndrome. (Pubmed Central) -  Oct 24, 2019   
    Approximately 40% of patients with CAS with documented VF and inferolateral J wave did not experience chest symptoms at the first VF, and could have been misdiagnosed as having ERS. The use of the spasm provocation test is considered essential to differentiate patients for optimal medical treatment.
  • ||||||||||  Pletal (cilostazol) / Otsuka
    Preclinical, Journal:  Description of a Novel Phosphodiesterase (PDE)-3 Inhibitor Protecting Mice From Ischemic Stroke Independent From Platelet Function. (Pubmed Central) -  Oct 18, 2019   
    Background and Purpose- Acetylsalicylic acid and clopidogrel are the 2 main antithrombotic drugs for secondary prevention in patients with ischemic stroke (IS) without indication for anticoagulation...Cilostazol, a specific phosphodiesterase (PDE)-3 inhibitor, protected from IS in clinical studies comprising mainly Asian populations...Conclusions- The novel PDE-3 inhibitor substance V protected mice from IS independent from platelet function. Pharmaceutical inactivation of PDE-3 might become a promising therapeutic approach to combat IS via inhibition of thromboinflammatory mechanisms and stabilization of the blood-brain barrier.
  • ||||||||||  cilostazol / Generic mfg.
    Trial completion, Phase classification, Trial completion date, Trial primary completion date:  CAS-CARE: Carotid Artery Stenting With Cilostazol Addition for Restenosis (clinicaltrials.gov) -  Oct 16, 2019   
    P=N/A,  N=707, Completed, 
    Pharmaceutical inactivation of PDE-3 might become a promising therapeutic approach to combat IS via inhibition of thromboinflammatory mechanisms and stabilization of the blood-brain barrier. Active, not recruiting --> Completed | Phase classification: P4 --> PN/A | Trial completion date: Mar 2019 --> Sep 2019 | Trial primary completion date: Mar 2017 --> Mar 2019